Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment
On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...
CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...
HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth
China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...
Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933
French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...
NMPA Seeks Public Input on Drug Trial Data Protection Measures
On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...
Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...
Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services
Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...
Pfizer Restructures China Operations to Boost Growth and Innovation
US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...
CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings
The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...
Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...
GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...
Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its...
Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...
AccurEdit Therapeutics Receives FDA Orphan Drug Designation for ATTR Treatment
China-based AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Orphan Drug Designation (ODD) from the US...
Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from...
Medbanks Reports 2024 Financial Results Amid Business Reorganization
Sipai Health Technology Co., Ltd (HKG: 0314), known as Medbanks, released its 2024 financial report....
AstraZeneca’s Imfinzi Approved in EU for Limited-Stage Small Cell Lung Cancer
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has received approval from the European Union (EU) for...
HutchMed and Innovent Announce Positive Results for Fruquintinib and Sintilimab in Renal Cell Carcinoma Trial
Chinese companies HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) and Innovent Biologics, Inc. (HKG: 1801)...
Convalife and XLement Launch AI-Powered Joint Lab for Drug Development Innovation
On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the...
Celregen Therapeutics Secures RMB100 Million for iPSC Regenerative Medicine Platform
Hangzhou-based Celregen Therapeutics, a specialist in cell stem regenerative medicine incubated by Fosun Health Capital,...